Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Actavis Inc       US9426831031

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
Actavis plc operates as an investment holding company.It is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand, brand generic, over-the-counter and biosimilar products.The company was founded on October 1, 2013 and is... 
Sector
Pharmaceuticals
Calendar
11/05Earnings Release
Surperformance© rating of Actavis Inc
Trading Rating : Investor Rating :
More about the company
Financials ($)
Sales 2014 12 558 M
EBIT 2014 3 631 M
Net income 2014 1 801 M
Debt 2014 14 868 M
Yield 2014 -
Sales 2015 15 375 M
EBIT 2015 5 315 M
Net income 2015 2 823 M
Debt 2015 10 963 M
Yield 2015 -
PER 2014 41,26
PER 2015 21,07
EV / Sales 2014 6,24x
EV / Sales 2015 4,84x
Capitalization 63 510 M
More Financials
Latest news on ACTAVIS INC
1d agoDJPfizer Results Will Play Second Fiddle to Dealmaking Outlook -- Earnings Prev..
2d ago ACTAVIS : Confirms Appeals Court Upholds Lo Loestrin® Fe Patent
3d ago ACTAVIS : Signs Option to Acquire Rhythm Subsidiary and its GI Development Produ..
3d ago ACTAVIS : Signs Option to Acquire Rhythm Subsidiary and its GI Development Produ..
5d ago Actavis, Sanofi among bidders for Omega Pharma- Bloomberg
5d ago Top Allergan holder Paulson urges deal with Shire - sources
5d ago TOP ALLERGAN HOLDER PAULSON URGES DE : sources
10/16 ACTAVIS : Confirms Generic Quillivant XR® Patent Challenge
10/10 EXCLUSIVE - TOP ACTAVIS HOLDER, FIDE : sources
10/09 Allergan raises outlook; says Valeant offer undervalues company
10/09 ACTAVIS : Ironwood and Actavis to Present Linaclotide Data at the American Colle..
10/07 EXCLUSIVE : Actavis plans new merger approach for Allergan - sources
More news
Comments 
Advertisement
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF